Binding of [3H]desglycinyl remacemide to rat brain membranes: Association with the benzomorphan attachment site of the N-methyl-D-aspartic acid receptor channel

Brain Research

Volumn 827, Issue 1-2, 1999, Pages 46-50

  Ahmed, M S ^a   Mather, A ^b   Enna, S J ^c  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Anticonvulsant; Desglycinyl remacemide; MK 801; Phencyclidine; Remacemide; SKF 10,047

Indexed keywords

1 METHYL 1,2 DIPHENYLETHYLAMINE; BENZOMORPHAN; DIZOCILPINE; HALOPERIDOL; N ALLYLNORMETAZOCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; SIGMA RECEPTOR LIGAND; TRITIUM; AMINO ACID RECEPTOR BLOCKING AGENT; BENZOMORPHAN DERIVATIVE; DIAGNOSTIC AGENT; DIZOCILPINE MALEATE; DRUG DERIVATIVE; MEMBRANE PROTEIN; NEUROLEPTIC AGENT; PHENAZOCINE; PHENCYCLIDINE; PHENETHYLAMINE DERIVATIVE; SK&F 10047;

ANIMAL TISSUE; ARTICLE; BINDING SITE; BRAIN MEMBRANE; CELL FRACTIONATION; CONTROLLED STUDY; ISOTOPE LABELING; LIGAND BINDING; MALE; MEMBRANE BINDING; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION; ANIMAL; BRAIN LEVEL; CHEMISTRY; DRUG EFFECT; METABOLISM; NERVE CELL; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZOMORPHANS; BINDING SITES; BRAIN CHEMISTRY; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; HALOPERIDOL; MALE; MEMBRANE PROTEINS; NEURONS; PHENAZOCINE; PHENCYCLIDINE; PHENETHYLAMINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SUBCELLULAR FRACTIONS; TRITIUM;

EID: 0033535631     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)01263-9     Document Type: Article

References (29)

1. J.P. Bennett, H.I. Yamamura, Neurotransmitter, hormone, or drug receptor binding methods, in: H.I. Yamamura, S.J. Enna, M.J. Kuhar (Eds.), Neurotransmitter Receptor Binding, 2nd edn., Raven Press, New York, 1985, pp. 61-89.
2. 1 receptors Eur. J. Pharmacol. 266:1994;131-138.
3. Chen H.S., Pellegrini J.W., Aggarwal S.K., Lei S.Z., Worach S., Jensen F.E., Lipton S.A. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J. Neurosci. 12:1992;4427-4436.
4. DeLander G.E., Wahl J.J. In vivo characterization of phencyclidine/sigma agonist-mediated inhibition of nociception. Eur. J. Pharmacol. 159:1989;149-156.
5. Grant K.A., Colombo G., Grant J., Rogawski M.A. Dizocilpine-like discriminative stimulus effects of low-affinity uncompetitive NMDA antagonists. Neuropharmacology. 35:1996;1709-1719.
6. Grauert M., Rho J.M., Subramaniam S., Rogawski M.A. N-methyl-D-aspartate receptor channel block by the enantiomeric 6,7-benzomorphans BIII277CL and BIII281CL. J. Pharmacol. Exp. Ther. 285:1998;767-776.
7. 3H ]ifenprodil binding to σ receptors in rat brain Eur. J. Pharmacol. 236:1993;159-163.
8. J.J.H. Hens, Methods in molecular biology, in: K.C. Rayne (Ed.), Neurotransmitter Methods, Vol. 72, Humana Press, Totowa, NJ, pp. 61-67.
9. 3H α-(+)-3-PPP label pharmacologically distinct sigma binding sites in guinea pig brain membranes Eur. J. Pharmacol. 193:1991;21-27.
10. Kupferburg H.J. Antiepileptic drug development program: a cooperative effort of government and industry. Epilepsia. 30:1989;551-556. Suppl. 1.
11. Meldrum B.S. Update on the mechanism of action of antiepileptic drugs. Epilepsia. 37:1996;54-511. Suppl. 6.
12. Monaghan D.T., Larsen H. NR1 and NR2 subunit contributions to N-methyl-D-aspartate receptor channel blocker pharmacology. J. Pharmacol. Exp. Ther. 280:1997;614-620.
13. K.T. Muir, G.C. Palmer, Remacemide, in: F. Pisani, E. Perucca, G. Avanzini, A. Richens (Eds.), New Antiepileptic Drugs (Epilepsy Res. Suppl. 3), Elsevier, Amsterdam, 1991, pp. 147-152.
14. Palmer G.C., Cregan E.C., Borrelli A.R., Harris E.W., Stagnitto M.L., Colombo P., Kaiser F.C., Murray R.J., Griffith R.C., Strand J.C. Neuroprotective actions of 2-amino-N-(1,2-diphenylethyl)-acetamide hydrochloride (FPL 13950) in animal models of hypoxia and global ischemia. J. Pharmacol. Exp. Ther. 274:1995;991-1000.
15. G.C. Palmer, J.B. Hutchison, Preclinical and clinical aspects of remacemide hydrochloride, in: P. Herrling (Ed.), Excitatory Amino Acids - Clinical Results with Antagonists, Academic Press, New York, 1997, pp. 109-120.
16. G.C. Palmer, R.J. Murray, D.J. McCarthy, Neuroprotective potential of the low affinity NMDA receptor antagonist, ARL 15896A R, in: L.M. Savage (Ed.), Ischemic Stroke: II. Advances in Understanding and Therapy, IBC Biomedical Library Series, Southborough, MA, 1996, pp. 34-64.
17. Palmer G.C., Stagnitto M.L., Garske G.E., Napier J.J., Harris E.W., Kaiser R.C., Griffith R.C., Woodhead J.H., White H.S., Wolf H.H., Swinyard E.A. Anticonvulsant efficacy and safety properties of 2-amino-N-(1,2-diphenylethyl)-acetamide hydrochloride. J. Pharmacol. Exp. Ther. 273:1995;1023-1031.
18. Palmer G.C., Stagnitto M.L., Ordy J.M., Griffith R.C., Napier J.J., Gentile R.J., Woodhead J.H., White H.S., Swinyard E.A. Preclinical profile of stereoisomers of the anticonvulsant remacemide in mice. Epilepsy Res. 8:1991;36-48.
19. Patsalos P.N., Sander J. Newer antiepileptic drugs: towards an improved risk-benefit ratio. Drug Safety. 11:1994;37-67.
20. 3H ]MK-801 binding to the N-methyl-D-aspartate receptor-ion channel complex by L-glutamate, glycine, and polymines J. Neurochem. 51:1988;830-836.
21. Rogawski M.A., Porter R.J. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol. Rev. 42:1990;223-286.
22. Rogawski M.A., Yamaguchi S.-I., Jones S.M., Rice K.C., Thurkauf A., Monin J.A. Anticonvulsant activity of the low affinity uncompetitive N-methyl-D-aspartate antagonist (±)-5-aminocarbonyl-10,11-dihydro-5-dibenzo[a,d]cycloheptan-5,10-imine (ADCI): Comparison with the structural analogs dizocilpine (MK-801) and carbamazepine. J. Pharmacol. Exp. Ther. 259:1991;30-37.
23. Rogers C., Cecyre D., Lemaire S. Presence of sigma and phencyclidine (PCP)-like receptors in membrane preparations of bovine adrenal medulla. Biochem. Pharmacol. 38:1989;2467-2472.
24. Ross S.B. Heterogeneous binding of sigma radioligands in the rat brain and liver: possible relationship to subforms of cytochrome P-450. Pharmacol. Toxicol. 68:1991;293-301.
25. Srinivasan J., Richens A., Davies A. The effect of the desglycinyl metabolite of remacemide hydrochloride (FPL 12495AA) and dizocilpine (MK-801) and endogenous amino acid release from mouse cortex. Br. J. Pharmacol. 116:1995;3087-3092.
26. 3H ] piperidine binding to the N-methyl-D-aspartate receptor complex in human brain J. Neurochem. 56:1991;1248-1254.
27. Submaramaniam S., Donevan S.D., Rogawski M.A. Block of the N-methyl-D-aspartate receptor by remacemide and its des-glycine metabolite. J. Pharmacol. Exp. Ther. 276:1996;161-168.
28. Subramaniam S., McGonigle P. Regional heterogeneity of polyamine effects on the N-methyl-D-aspartate receptor in rat brain. J. Neurochem. 60:1993;2276-2284.
29. Zhou G.Z., Katki A.G., Schwartz S., Munson P.J., Rodbard D. Quantitative characterization of multiple binding sites for phencyclidine and N-allylnormetazocine in membranes from rat and guinea pig brain. Neuropharmacology. 30:1991;775-786.